Francois-Clement Bidard (François-Clément Bidard, F C Bidard, F-C Bidard)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 46

Top Venues

Oncogene

Breast cancer research and treatment

Cancers

JNCI cancer spectrum

Institut Curie

Université Paris-Sud (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institut Curie

France

Professor of Medical Oncology :: UVSQ / Paris Saclay University

Institut Curie

France

Medical Oncologist (junior/senior)

Memorial Sloan Kettering Cancer Center

United States

Visiting Investigator (post-doc)

Institut Curie

France

Medical Oncologist (Assistant Professor)

Education History

Université Paris-Sud

France

PHD

Ecole normale supérieure

France

MSC

Publications

Alexander W Wyatt, Saskia Litière, Francois-Clement Bidard, Luc Cabel, Lars Dyrskjøt, Chris A Karlovich, Klaus Pantel, Joan Petrie, Reena Philip, Hillary S Andrews, Paz J Vellanki, Sofie H Tolmeijer, Xenia Villalobos Alberu, Christian Alfano, Jan Bogaerts, Emiliano Calvo, Helen X Chen, Rodrigo De Almeida Toledo, Elisabeth G E de Vries, Lesley Seymour, Scott A Laurie, Elena Garralda
Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Stephanie H Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database. Breast cancer research and treatment (2024)
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne G C Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, Francois-Clement Bidard
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43 (16) (2024)
Stephanie H Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database. Breast cancer research and treatment 204 (3) (2024)
Aditya Bardia, Javier Cortes, Francois-Clement Bidard, Patrick Neven, José Angel García-Saenz, Philippe Aftimos, Joyce O'Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia G Kaklamani
Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne G C Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, Francois-Clement Bidard
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43 (16) (2024)
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne G C Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, Francois-Clement Bidard
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43 (16) (2024)
Stephanie H Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database. Breast cancer research and treatment 204 (3) (2024)
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne G C Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, Francois-Clement Bidard
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene (2024)
Antoine Vasseur, Luc Cabel, Caroline Hego, Wissam Takka, Olfa Trabelsi Grati, Benjamin Renouf, Florence Lerebours, Delphine Loirat, Etienne G C Brain, Paul Cottu, Marie-Paule Sablin, Jean-Yves Pierga, Céline Callens, Shufang Renault, Francois-Clement Bidard
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43 (16) (2024)
Toulsie Ramtohul, Victoire Lepagney, Claire Bonneau, Maxime Jin, Emmanuelle Menet, Juliette Sauge, Enora Laas, Emanuela Romano, Diana Bello-Roufai, Fatima Mechta-Grigoriou, Anne-Vincent Salomon, Francois-Clement Bidard, Adriana Langer, Caroline Malhaire, Luc Cabel, Hervé J Brisse, Anne Tardivon
Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology 312 (3) (2024)
Stephanie H Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database. Breast cancer research and treatment 204 (3) (2024)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Francois-Clement Bidard, Nicolas Kiavue, William Jacot, Thomas Bachelot, Sylvain Dureau, Hughes Bourgeois, Anthony Goncalves, Etienne G C Brain, Sylvain Ladoire, Florence Dalenc, Joseph Gligorov, Luis Teixeira, George Emile, Jean-Marc Ferrero, Delphine Loirat, Luc Cabel, Amir Kadi, Véronique Diéras, Catherine Alix-Panabières, Jean-Yves Pierga
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Nicholas C Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen K L Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Jang-Yeon Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bidard
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment. Future oncology (London, England) (2023)
Lounes Djerroudi, Luc Cabel, Francois-Clement Bidard, Anne-Vincent Salomon
Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy? Journal of the National Cancer Institute 114 (11) (2022)
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof de Julio, Luigi M Terracciano, Claudia Lengerke, Rinath M Jeselsohn, Robert C Doebele, Francois-Clement Bidard, Elisabetta Marangoni, Charlotte C K Ng, Salvatore Piscuoglio
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications biology 5 (1) (2022)
Joanna Cyrta, Camille Benoist, Julien Masliah-Planchon, Andre F Vieira, Gaëlle Pierron, Laëtitia Furhmann, Camille Richardot, Martial Caly, Renaud Leclere, Odette Mariani, Elisabeth Da Maia, Frédérique Larousserie, Jean Guillaume Féron, Matthieu Carton, Victor Renault, Francois-Clement Bidard, Anne-Vincent Salomon
Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 35 (11) (2022)
Khadidja Zeyneb Klouch, Marc-Henri Stern, Olfa Trabelsi-Grati, Nicolas Kiavue, Luc Cabel, Amanda Bortolini Silveira, Caroline Hego, Aurore Rampanou, Tatiana Popova, Guillaume Bataillon, Sarah Nasr, Charlotte Proudhon, Marc Michel, Victor Renault, Julien Masliah Planchon, Anne-Vincent Salomon, Jean-Yves Pierga, Ivan Bieche, Shufang Renault, Francois-Clement Bidard
Microsatellite instability detection in breast cancer using drop-off droplet digital PCR. Oncogene 41 (49) (2022)
Ezgi Tulukcuoglu Guneri, Emile Lakis, Ismail Hajji, Elian Martin, Jerome Champ, Aurore Rampanou, Jean-Yves Pierga, Jean-Louis Viovy, Charlotte Proudhon, Francois-Clement Bidard, Stéphanie Descroix
Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach. Cancers 14 (8) (2022)
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof de Julio, Luigi M Terracciano, Claudia Lengerke, Rinath M Jeselsohn, Robert C Doebele, Francois-Clement Bidard, Elisabetta Marangoni, Charlotte C K Ng, Salvatore Piscuoglio
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Communications biology 5 (1) (2022)
Lorenzo Gerratana, Jean-Yves Pierga, James M Reuben, Andrew A Davis, Firas H Wehbe, Luc Dirix, Tanja Fehm, Franco Nolé, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Jose A Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Marta Bonotto, Angela Fernandez de Lascoiti, Leticia De Mattos-Arruda, Michail Ignatiadis, Maria-Teresa Sandri, Daniele Generali, Carmine De Angelis, Sarah-Jane Dawson, Wolfgang Janni, Vicente Carañana, Sabine Riethdorf, Erich-Franz Solomayer, Fabio Puglisi, Mario Giuliano, Klaus Pantel, Francois-Clement Bidard, Massimo Cristofanilli
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. The oncologist 27 (7) (2022)
Clelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, Stelly Ballet, Anne-Vincent Salomon, Perrine Vuagnat, Audrey Bellesoeur, Jean-Yves Pierga, Marc-Henri Stern, Francois-Clement Bidard, Florence Lerebours
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. Cancers 14 (9) (2022)
Florence Coussy, Francois-Clement Bidard
Expanding biomarkers for PARP inhibitors. Nature cancer 3 (10) (2022)
Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, Francois-Clement Bidard
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast cancer research : BCR 23 (1) (2021)
Renaud Sabatier, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, Francois-Clement Bidard, Jean-Marc Extra, Patrick Sfumato, Anthony Goncalves
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers 13 (1) (2021)
Laia Richart, Francois-Clement Bidard, Raphaël Margueron
Enhancer rewiring in tumors: an opportunity for therapeutic intervention. Oncogene 40 (20) (2021)
Romain-David Seban, Anne Donnadieu, Gabrielle Journo, Francois-Clement Bidard, Capucine Richard, Roman Rouzier, Laurence Champion
18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics (Basel, Switzerland) 11 (8) (2021)
Luc Cabel, Frédérique Berger, Paul-Henri Cottu, Delphine Loirat, Aurore Rampanou, Etienne Brain, Stacy Cyrille, Hugues Bourgeois, Nicolas Kiavue, Elise Deluche, Sylvain Ladoire, Mario Campone, Jean-Yves Pierga, Francois-Clement Bidard
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. British journal of cancer 124 (7) (2021)
Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi, Anne Patsouris, Josselin Annic, Lounes Djerroudi, Marion Lavigne, Jean-Yves Pierga, Paul Coppo, Francois-Clement Bidard
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. Breast cancer research : BCR 23 (1) (2021)
Jean-Christophe Tille, André F Vieira, Caroline Saint-Martin, Lounes Djerroudi, Laëtitia Furhmann, Francois-Clement Bidard, Youlia Kirova, Anne Tardivon, Fabien Reyal, Matthieu Carton, Anne Vincent-Salomon
Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 33 (11) (2020)
Emmanuelle Jeannot, Lauren Darrigues, Marc Michel, Marc-Henri Stern, Jean-Yves Pierga, Aurore Rampanou, Samia Melaabi, Camille Benoist, Ivan Bièche, Anne Vincent-Salomon, Radouane El Ayachy, Aurélien Noret, Nicolas Epaillard, Luc Cabel, Francois-Clement Bidard, Charlotte Proudhon
A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene 39 (14) (2020)
Luc Cabel, Charlotte Proudhon, Emanuela Romano, Nicolas Girard, Olivier Lantz, Marc-Henri Stern, Jean-Yves Pierga, Francois-Clement Bidard
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature reviews. Clinical oncology 15 (10) (2019)
Nicolas Kiavue, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Celine Callens, Florence Lerebours, Jean-Yves Pierga, Francois-Clement Bidard
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene 39 (3) (2019)
Laura Thery, Alessandra Meddis, Luc Cabel, Charlotte Proudhon, Aurelien Latouche, Jean-Yves Pierga, Francois-Clement Bidard
Circulating Tumor Cells in Early Breast Cancer. JNCI cancer spectrum 3 (2) (2019)
William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D'Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast cancer research : BCR 21 (1) (2019)
Luc Cabel, Charles Decraene, Ivan Bieche, Jean-Yves Pierga, Mostefa Bennamoun, David Fuks, Jean-Marc Ferraz, Marine Lefevre, Sylvain Baulande, Virginie Bernard, Sophie Vacher, Pascale Mariani, Charlotte Proudhon, Francois-Clement Bidard, Christophe Louvet
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. Cancers 11 (3) (2019)
Marcela Carausu, Samia Melaabi, Jean-Yves Pierga, Francois-Clement Bidard, Luc Cabel
ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer. Journal of breast cancer 23 (2) (2019)
Ryan J O Dowling, Joseph A Sparano, Pamela J Goodwin, Francois-Clement Bidard, David W Cescon, Sarat Chandarlapaty, Joseph O Deasy, Mitch Dowsett, Robert C Gray, Norah L Henry, Funda Meric-Bernstam, Jane Perlmutter, George W Sledge, Mangesh A Thorat, Scott V Bratman, Lisa Anne Carey, Martin C Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J Jerzak, Larissa A Korde, Ana Elisa Lohmann, Eleftherios P Mamounas, Wendy R Parulekar, Meredith M Regan, Daniel Schramek, Vuk Stambolic, Timothy J Whelan, Antonio C Wolff, James R Woodgett, Kevin Kalinsky, Daniel F Hayes
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI cancer spectrum 3 (4) (2019)
Ryan J O Dowling, Kevin Kalinsky, Daniel F Hayes, Francois-Clement Bidard, David W Cescon, Sarat Chandarlapaty, Joseph O Deasy, Mitch Dowsett, Robert C Gray, Norah L Henry, Funda Meric-Bernstam, Jane Perlmutter, George W Sledge, Scott V Bratman, Lisa Anne Carey, Martin C Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J Jerzak, Larissa A Korde, Ana Elisa Lohmann, Eleftherios P Mamounas, Wendy R Parulekar, Meredith M Regan, Daniel Schramek, Vuk Stambolic, Mangesh A Thorat, Timothy J Whelan, Antonio C Wolff, James R Woodgett, Joseph A Sparano, Pamela J Goodwin
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI cancer spectrum 3 (4) (2019)
Marie-Laure Tanguy, Luc Cabel, Fréderique Berger, Jean-Yves Pierga, Alexia Savignoni, Francois-Clement Bidard
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. NPJ breast cancer 4 (2018)
Luc Cabel, Emmanuelle Jeannot, Ivan Bieche, Sophie Vacher, Celine Callens, Louis Bazire, Adeline Morel, Alice Bernard-Tessier, Walid Chemlali, Anne Schnitzler, Astrid Lièvre, Joelle Otz, Mathieu Minsat, Anne Vincent-Salomon, Jean-Yves Pierga, Bruno Buecher, Pascale Mariani, Charlotte Proudhon, Francois-Clement Bidard, Wulfran Cacheux
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (22) (2018)
G Beinse, F Berger, P Cottu, M-E Dujaric, I Kriegel, M-N Guilhaume, V Diéras, L Cabel, J-Y Pierga, Francois-Clement Bidard
Circulating tumor cell count and thrombosis in metastatic breast cancer. Journal of thrombosis and haemostasis : JTH 15 (10) (2017)

Francois-Clement Bidard.css-eqlu8i{font-size:small;padding-left:4px;} (François-Clément Bidard, F C Bidard, F-C Bidard)

Publication Activity (10 Years)

Top Topics

Top Venues

Francois-Clement Bidard (François-Clément Bidard, F C Bidard, F-C Bidard)